Only two patients failed to complete more than half of the 45 items of the Selleckchem EGFR inhibitor prototype questionnaire and were considered unexploitable. Patient characteristics GSK2126458 mouse The characteristics of patients returning their ADEOS questionnaires are presented in Table 1. The mean age of the sample was 71.2 ± 8.9 years and 34.8% had previously experienced a fracture. The mean time since diagnosis of osteoporosis was 5.4 ± 4.7 years and 87.3% had undergone
bone densitometry. The most commonly prescribed treatments for osteoporosis were bisphosphonates (in 75.7% of patients) and a little over half were prescribed a treatment to be taken weekly (52.9%). No difference between patients returning their ADEOS questionnaires and those who did not return them was observed for any of these variables (data not shown). Measures of adherence Previous adherence to osteoporosis treatment was determined using the MPR for the entire treatment period. Mean MPR values and the proportion of adherent patients using cut-offs of 0.80 and 0.68 are presented in Table 1. There
was no difference in MPR values between the patients returning their ADEOS questionnaires and those not returning them for any of the MPR variables studies, with the exception of the proportion of patients adherent over their entire treatment period using a threshold of 0.80, which was higher in patients returning their questionnaire (p = 0.021). According to the judgement of the GP as to whether their patients were adherent to treatment Olopatadine or not, 97.1% of patients were considered OSI-906 in vivo to be adherent all or most of the time (Table 1), again with no significant difference between patients returning or not returning their questionnaires (data not shown). For patients returning an MMAS questionnaire, the mean MMAS score was 3.5 ± 0.8.
The distribution of MMAS score is presented in Fig. 1, with 62.9% of respondents scoring 4 on this rating scale and thus being considered as adherent. Fig. 1 Distribution of MMAS (left) and ADEOS-12 (right) scores. Data are presented as absolute numbers of patients. ADEOS-12: 12-item adherence and osteoporosis questionnaire; MMAS Morisky Medication Adherence Scale Adherence measured by the MMAS was significantly associated with the physician’s judgement of patient adherence (p = 0.0001). However, the correlation between the MMAS and the MPR for the most recent treatment was limited (r 2 = 0.1195; p = 0.034), and there was no association between MPR and the physicians judgement (p = 0.749). Item selection and scoring Overall, 12 items were associated with the MMAS score at a probability threshold of ≤ 0.05. These are listed in Table 2. With the exception of Item 23 (19 patients did not reply to this question), data were missing for less than 5% of patients for the selected items (one to ten patients according to the item). The scoring system is described in the questionnaire provided in Electronic Supplementary Material. Three types of question were retained in the questionnaire (Table 3).